These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

958 related items for PubMed ID: 32482128

  • 1. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Quarato CMI, Foschino Barbaro MP.
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [No Abstract] [Full Text] [Related]

  • 2. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, Price RG, Galkin DV, Azmi J, Mouneimne D, Albers FC, Chapman KR.
    Respir Res; 2021 May 10; 22(1):144. PubMed ID: 33971856
    [Abstract] [Full Text] [Related]

  • 3. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, Liu MC.
    Allergy; 2019 Sep 10; 74(9):1716-1726. PubMed ID: 31049972
    [Abstract] [Full Text] [Related]

  • 4. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
    Respir Med; 2019 Sep 10; 154():69-75. PubMed ID: 31220806
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE, Resta E, Povero M, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro MPF.
    Sci Rep; 2021 Mar 09; 11(1):5453. PubMed ID: 33750842
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C, Calabrese C, Barbuto S, Busceti MT, Preianò M, Gallelli L, Savino R, Vatrella A, Pelaia G.
    Pulm Pharmacol Ther; 2019 Feb 09; 54():25-30. PubMed ID: 30414440
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M.
    Ann Allergy Asthma Immunol; 2018 May 09; 120(5):504-511.e4. PubMed ID: 29409951
    [Abstract] [Full Text] [Related]

  • 16. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
    Tepetam FM, Akyildiz AB, Özden Ş, Örcen C, Yakut T, Atik Ö.
    Medicine (Baltimore); 2023 May 05; 102(18):e33660. PubMed ID: 37144999
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan 18; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract] [Full Text] [Related]

  • 19. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
    Nopsopon T, Barrett NA, Phipatanakul W, Laidlaw TM, Weiss ST, Akenroye A.
    Allergy; 2024 May 18; 79(5):1195-1207. PubMed ID: 38164813
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.